1H-[1,2,3]triazolo[4,5-H]quinazoline compounds as protein kinase inhibitors
The 1H-[1,2,3]triazolo[4,5-h]quinazoline compounds address the limitations of existing CDK inhibitors by providing enhanced metabolic stability and clearance rates, effectively treating CDK-related diseases like cancer and inflammation.
JP2026519596APending Publication Date: 2026-06-16CHENGDU CYNOGEN BIO-PHARM TECH CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- CHENGDU CYNOGEN BIO-PHARM TECH CO LTD
- Filing Date
- 2024-05-31
- Publication Date
- 2026-06-16
AI Technical Summary
Technical Problem
Existing CDK inhibitors face challenges such as lack of efficacy in solid tumors, toxicity issues, and insufficient selectivity for CDK subtypes, limiting their effectiveness in treating CDK-related diseases like cancer and inflammation.
Method used
Development of 1H-[1,2,3]triazolo[4,5-h]quinazoline compounds as potent inhibitors of cyclin-dependent kinases (CDKs) with improved pharmacokinetic properties, including enhanced metabolic stability and clearance rates.
Benefits of technology
The 1H-[1,2,3]triazolo[4,5-h]quinazoline compounds demonstrate significant improvement in metabolic stability and clearance rates, offering a more effective treatment for CDK-related diseases, including various cancers and inflammation.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026519596000001_ABST
Abstract
A 1H-[1,2,3]triazolo[4,5-H]quinazoline compound of general formula (I) is provided, which can be used to treat cell proliferation disorders. The compound is an effective inhibitor of cyclin-dependent kinase (CDK). [C1] TIFF2026519596000150.tif51156
Need to check novelty before this filing date? Find Prior Art